THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES

Sri International, Menlo Park CA

Investigators

Abstract

Metformin is one of the most widely used glucose-lowering drugs that is effectively used for the current treatment of type 2 diabetes mellitus. In addition to anti-diabetic action, metformin appears to possess important additional properties that may be pharmacologically relevant to long-term human health and welfare. Translational studies are therefore being undertaken in rodents within IRP, NIA, to evaluate potentially beneficial actions of metformin on a number of pharmacodynamics measures of relevance to health in rodents administered normal and assorted diets ? including high fat. Pharmacokinetics ? specifically, metformin blood and tissue levels are required to interpret pharmacodynamic data and aid in translation studies across species ? with an emphasis on humans. This Task Order supports the quantitative analysis of metformin drug levels in plasma and tissue samples generated in IRP NIA research studies.